DK2341937T3 - Sammensætning til behandling af en sygdom - Google Patents
Sammensætning til behandling af en sygdom Download PDFInfo
- Publication number
- DK2341937T3 DK2341937T3 DK09782400.7T DK09782400T DK2341937T3 DK 2341937 T3 DK2341937 T3 DK 2341937T3 DK 09782400 T DK09782400 T DK 09782400T DK 2341937 T3 DK2341937 T3 DK 2341937T3
- Authority
- DK
- Denmark
- Prior art keywords
- domain
- chain
- agent
- seq
- antibody
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Claims (12)
1. Kit, omfattende et separat middel til at aktivere regulatoriske CD4+CD25+-T-celler og methotrexat, hvor midlet er et humaniseret anti-CD4-antistof, som omfatter et V-domæne af en H-kæde og et V-domæne af en L-kæde, og hvor: (a) V-domænet af H-kæden omfatter sekvenserne DCRMY, VISVKSE-NYGANYAESVRG og SYYRYDVGAWFAY, og V-domænet af L-kæden omfatter sekvenserne RASKSVSTSGYSYIY, LASILES og QHSRELPWT; og/eller (b) V-domænet af H-kæden har mindst 80% sekvensidentitet med SEQ ID No: 1 og V-domænet af L-kæden har mindst 80% sekvensidentitet med SEQ ID No: 2.
2. Kit ifølge krav 1, hvor det humaniserede anti-CD4-antistof omfatter et V-domæne af H-kæden defineret med SEQ ID No: 1 og et V-domæne af L-kæden defineret med SEQ ID NO: 2.
3. Middel, der er i stand til at aktivere regulatoriske CD4+CD25+-T-celler og methotrexat som et kombineret præparat til samtidig, separat eller sekventiel anvendelse i medicin, hvor midlet er et humaniseret anti-CD4-antistof, som omfatter et V-domæne af en H-kæde og et V-domæne af en L-kæde, og hvor: (a) V-domænet af H-kæden omfatter sekvenserne DCRMY, VISVKSE-NYGANYAESVRG og SYYRYDVGAWFAY, og V-domænet af L-kæden omfatter sekvenserne RASKSVSTSGYSYIY, LASILES og QHSRELPWT; og/eller (b) V-domænet af H-kæden har mindst 80% sekvensidentitet med SEQ ID No: 1 og V-domænet af L-kæden har mindst 80% sekvensidentitet med SEQ ID No: 2.
4. Middel, der er i stand til at aktivere regulatoriske CD4+CD25+-T-celler til anvendelse i behandlingen af en reumatoid sygdom, hvor midlet er til samtidig, separat eller sekventiel anvendelse med methotrexat som en kombinationsterapi, hvor midlet er et humaniseret anti-CD4-antistof, som omfatter et V-domæne af en H-kæde og et V-domæne af en L-kæde, og hvor: (a) V-domænet af H-kæden omfatter sekvenserne DCRMY, VISVKSENYGANYA-ESVRG and SYYRYDVGAWFAY, og V-domænet af L-kæden omfatter sekvenserne RASKSVSTSGYSYIY, LASILES og QHSRELPWT; og/eller (b) V-domænet af H-kæden har mindst 80% sekvensidentitet med SEQ ID No: 1 og V-domænet af L-kæden har mindst 80% sekvensidentitet med SEQ ID No: 2.
5. Middel, der er i stand til at aktivere regulatoriske CD4+CD25+-T-celler til anvendelse i behandlingen af en reumatoid sygdom hos en patient, hvor patienten gennemgår methotrexat-behandling, hvor midlet er et humaniseret anti-CD4-antistof, som omfatter et V-domæne af en H-kæde og et V-domæne af en L-kæde, og hvor: (a) V-domænet af H-kæden omfatter sekvenserne DCRMY, VISVKSENYGANYAESVRG og SYYRYDVGAWFAY, og V-domænet af L-kæden omfatter sekvenserne RASKSVSTSGYSYIY, LASI-LES og QHSRELPWT; og/eller (b) V-domænet af H-kæden har mindst 80% sekvensidentitet med SEQ ID No: 1 og V-domænet af L-kæden har mindst 80% sekvensidentitet med SEQ ID No: 2.
6. Sammensætning omfattende methotrexat til anvendelse i behandlingen af en reumatoid sygdom hos en patient, hvor patienten gennemgår behandling med et middel, som er i stand til at aktivere regulatoriske CD4+CD25+-T-celler, hvor midlet er et humaniseret anti-CD4-antistof, som omfatter et V-domæne af en H-kæde, og et V-domæne af en L-kæde, og hvor: (a) V-domænet af H-kæden omfatter sekvenserne DCRMY, VISVKSENYGANYAESVRG og SYYRYDVGAWFAY, og V-domænet af L-kæden omfatter sekvenserne RASKSVSTSGYSYIY, LASILES og QHSRELPWT; og/eller (b) V-domænet af H-kæden har mindst 80% sekvensidentitet med SEQ ID No: 1 og V-domænet af L-kæden har mindst 80% sekvensidentitet med SEQ ID No: 2.
7. Middel, der er i stand til at aktivere regulatoriske CD4+CD25+-T-celler til anvendelse ifølge krav 4 i behandlingen af en reumatoid sygdom hos en patient, som ikke reagerer på behandling med et sygdomsmodificerende anti-reumatiske lægemiddel (DMARD), fortrinsvis hvor DMARD er methotrexat.
8. Middel eller sammensætning til anvendelse ifølge et af kravene 3 til 7, hvor den reumatoide sygdom er udvalgt fra reumatoid artritis, psoriasis artritis, juvenil reumatoid artritis og ankyloserende spondylitis, og hvor den reumatoide sygdom fortrinsvis er reumatoid artritis.
9. Middel eller sammensætning til anvendelse ifølge et af kravene 3 til 8, hvor midlet er egnet til indgivelse som en enkelt dosering, som en del af en flerhed af doseringer, eller en gang om ugen, hver anden uge, hver tredje uge eller hver fjerde uge.
10. Middel eller sammensætning til anvendelse ifølge et af kravene 3 til 9, som skal indgives med et yderligere terapeutisk middel, der er egnet til at behandle sygdommen, og er udvalgt blandt et ikke-steroidt antiinflammato-risk medikament, et antiinflammatorisk steroid, en guldsammensætning, et medikament mod malaria, folinsyre, cyclosporin, leflunomid, azathioprin, sul-fasalazin, d-penicillamin, cyclophosphamid, mycophenoat, minocyclin og chlorambucil.
11. Middel eller sammensætning til anvendelse ifølge et af kravene 3 til 10, hvor det humaniserede anti-CD4-antistof omfatter et V-domæne af H-kæden defineret med SEQ ID No: 1 og et V-domæne af L-kæden defineret med SEQ ID NO: 2.
12. Fremgangsmåde omfattende fremstilling af et kit omfattende midlet og methotrexat ifølge krav 1 eller krav 2.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0817810A GB0817810D0 (en) | 2008-09-29 | 2008-09-29 | Agent for treating disease |
GB0817811A GB0817811D0 (en) | 2008-09-29 | 2008-09-29 | Agent for treating disease |
GB0817809A GB0817809D0 (en) | 2008-09-29 | 2008-09-29 | Agent for treating disease |
PCT/EP2009/052811 WO2009124815A1 (en) | 2008-03-13 | 2009-03-10 | Agent for treating disease |
PCT/EP2009/052810 WO2009112502A1 (en) | 2008-03-13 | 2009-03-10 | Agent for treating disease |
PCT/EP2009/052809 WO2009121690A1 (en) | 2008-03-13 | 2009-03-10 | Agent for treating disease |
PCT/EP2009/061210 WO2010034590A1 (en) | 2008-09-29 | 2009-08-31 | Composition for treating disease |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2341937T3 true DK2341937T3 (da) | 2015-02-09 |
Family
ID=41138980
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK09782400.7T DK2341937T3 (da) | 2008-09-29 | 2009-08-31 | Sammensætning til behandling af en sygdom |
Country Status (17)
Country | Link |
---|---|
US (1) | US20110229465A1 (da) |
JP (2) | JP2012504110A (da) |
KR (1) | KR20110061630A (da) |
CN (1) | CN102215867B (da) |
AU (1) | AU2009296078B2 (da) |
BR (1) | BRPI0919489A2 (da) |
CA (1) | CA2738598C (da) |
CR (1) | CR20110226A (da) |
DK (1) | DK2341937T3 (da) |
ES (1) | ES2528419T3 (da) |
HK (1) | HK1154797A1 (da) |
IL (1) | IL211904A (da) |
MX (1) | MX2011003335A (da) |
PT (1) | PT2341937E (da) |
RU (1) | RU2531548C2 (da) |
SG (1) | SG194362A1 (da) |
WO (1) | WO2010034590A1 (da) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1460088A1 (en) | 2003-03-21 | 2004-09-22 | Biotest AG | Humanized anti-CD4 antibody with immunosuppressive properties |
MX2010010028A (es) * | 2008-03-13 | 2011-08-17 | Biotest Ag | Agente para tratar enfermedad. |
SG190627A1 (en) * | 2008-03-13 | 2013-06-28 | Biotest Ag | Agent for treating disease |
EP2262838B1 (en) * | 2008-03-13 | 2016-04-13 | Biotest AG | Agent for treating disease |
GB0920944D0 (en) | 2009-11-30 | 2010-01-13 | Biotest Ag | Agents for treating disease |
EP3019193B1 (en) * | 2013-07-10 | 2019-09-25 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Apoptotic cell-mediated induction of antigen specific regulatory t-cells for the therapy of autoimmune diseases in animals and humans |
GB202017681D0 (en) * | 2020-11-09 | 2020-12-23 | T Balance Therapeutics Gmbh | Anti-CD4 antibody or fragment thereof for medical use |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5690933A (en) * | 1989-05-31 | 1997-11-25 | Glaxo Wellcome Inc. | Monoclonal antibodies for inducing tolerance |
US20020099179A1 (en) * | 1989-12-21 | 2002-07-25 | Linda K. Jolliffe | Cdr-grafted antibodies |
US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US7084260B1 (en) * | 1996-10-10 | 2006-08-01 | Genpharm International, Inc. | High affinity human antibodies and human antibodies against human antigens |
EP0512112B1 (en) * | 1990-11-27 | 1997-05-28 | Biogen, Inc. | Anti cd-4 antibodies blocking hiv-induced syncytia |
US7192584B2 (en) * | 1991-03-18 | 2007-03-20 | Centocor, Inc. | Methods of treating psoriasis with anti-TNF antibodies |
US6136310A (en) * | 1991-07-25 | 2000-10-24 | Idec Pharmaceuticals Corporation | Recombinant anti-CD4 antibodies for human therapy |
JPH05244982A (ja) * | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化b−b10 |
US5777085A (en) * | 1991-12-20 | 1998-07-07 | Protein Design Labs, Inc. | Humanized antibodies reactive with GPIIB/IIIA |
US6270766B1 (en) * | 1992-10-08 | 2001-08-07 | The Kennedy Institute Of Rheumatology | Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease |
DK0614984T4 (da) * | 1993-03-05 | 2010-12-20 | Bayer Healthcare Llc | Humane monoklonale anti-TNF-alfa-antistoffer |
EP0631783A1 (en) * | 1993-06-03 | 1995-01-04 | Mitsubishi Chemical Corporation | Antiviral combinations of 2',3'-di-deoxyribonucleosides with 6-benzyl-1-ethoxymethyl-5-substituted uracil derivatives |
US20020068057A1 (en) * | 1994-03-10 | 2002-06-06 | Marc Feldmann | Treatment of autoimmune and inflammatory disorders |
US20010056066A1 (en) * | 1996-07-26 | 2001-12-27 | Smithkline Beecham Corporation | Method of treating immune cell mediated systemic diseases |
DE19722888A1 (de) * | 1997-05-28 | 1998-12-03 | Thomas Prof Dr Huenig | Human-CD28 spezifische monoklonale Antikörper zur antigenunspezifischen Aktivierung von T-Lymphozyten |
DE60042785D1 (de) * | 1999-06-09 | 2009-10-01 | Immunomedics Inc | Immuntherapie von autoimmunerkrankungen durch die verwendung von b-zell spezifischen antikörpern |
AU2001275186A1 (en) * | 2000-06-02 | 2001-12-17 | Nicole Kirchhof | Immunotherapeutic method to prevent islet cell rejection |
KR20040023565A (ko) * | 2000-09-18 | 2004-03-18 | 아이덱 파마슈티칼즈 코포레이션 | B 세포 고갈/면역조절 항체 조합을 이용한 자가면역질환의 치료를 위한 조합 요법 |
DE10050935A1 (de) * | 2000-10-11 | 2002-05-02 | Tegenero Gmbh | Verwendung CD28 spezifischer monoklonaler Antikörper zur Stimulation von Blutzellen, welche kein CD28 tragen |
US6726923B2 (en) * | 2001-01-16 | 2004-04-27 | Vascular Therapies, Llc | Apparatus and methods for preventing or treating failure of hemodialysis vascular access and other vascular grafts |
WO2002072759A2 (en) * | 2001-03-07 | 2002-09-19 | Children's Medical Center Corporation | Method to screen peptide display libraries using minicell display |
US20040136949A1 (en) * | 2001-04-24 | 2004-07-15 | Matthias Grell | Combination therapy using anti-angiogenic agents and tnf alpha |
US7541443B2 (en) * | 2001-06-14 | 2009-06-02 | Tolerrx, Inc. | Anti-CD4 antibodies |
AU2002357427A1 (en) * | 2001-12-04 | 2003-06-17 | Tegenero Ag | Peptide or protein containing a c'-d loop of the cd28 receptor family |
DE10212108A1 (de) * | 2002-03-13 | 2003-10-02 | Tegenero Ag | Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer pharmazeutischen Zusammensetzung |
DE10230223A1 (de) * | 2002-07-04 | 2004-01-22 | Tegenero Ag | Mikropartikel mit CD28-spezifischen monoklonalen Antikörpern |
US7501494B2 (en) * | 2003-01-15 | 2009-03-10 | United Biomedical, Inc. | Designed deimmunized monoclonal antibodies for protection against HIV exposure and treatment of HIV infection |
EP1460088A1 (en) * | 2003-03-21 | 2004-09-22 | Biotest AG | Humanized anti-CD4 antibody with immunosuppressive properties |
JP2006522811A (ja) * | 2003-04-09 | 2006-10-05 | ジェネンテック・インコーポレーテッド | TNFαインヒビターに対して不十分な反応を示す患者の自己免疫疾患治療法 |
GB0314461D0 (en) * | 2003-06-20 | 2003-07-23 | Isis Innovation | Suppression of transplant rejection |
EP1600164A3 (de) * | 2003-09-22 | 2006-05-17 | TeGenero AG | Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer Pharmazeutischen Zusammensetzung mit dosisabhängiger Wirkung |
DE10352900A1 (de) * | 2003-11-11 | 2005-06-16 | Tegenero Ag | Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung von B-CLL |
WO2006035876A1 (ja) * | 2004-09-29 | 2006-04-06 | Kowa Co., Ltd. | 関節リウマチの予防及び/又は治療薬 |
DE102004063494A1 (de) * | 2004-12-23 | 2006-07-13 | Tegenero Ag | Antikörper |
JP4730733B2 (ja) * | 2005-05-02 | 2011-07-20 | 国立大学法人京都大学 | 4型葉酸受容体の発現を指標とした制御性t細胞の検出方法、及び免疫賦活剤 |
SG163615A1 (en) * | 2005-07-11 | 2010-08-30 | Macrogenics Inc | Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity |
BRPI0615397B1 (pt) * | 2005-08-26 | 2023-10-03 | Roche Glycart Ag | Anticorpo anti-cd20, composição farmacêutica que o contém e uso do mesmo |
JP2009530290A (ja) * | 2006-03-16 | 2009-08-27 | ジェネンテック・インコーポレーテッド | Cd4抗体を使用するループスの治療方法 |
SG190627A1 (en) | 2008-03-13 | 2013-06-28 | Biotest Ag | Agent for treating disease |
EP2262838B1 (en) | 2008-03-13 | 2016-04-13 | Biotest AG | Agent for treating disease |
MX2010010028A (es) | 2008-03-13 | 2011-08-17 | Biotest Ag | Agente para tratar enfermedad. |
ES2351456B1 (es) * | 2009-06-24 | 2011-11-28 | Fundacio Institut De Recerca De L'hospital Universitari Vall D'hebron | Metodo in vitro para el pronostico o prediccion de la respuesta por parte de pacientes con artritis reumatoide al tratamiento con agentes que reconocen el receptor de membrana cd20 de los linfocitos b |
-
2009
- 2009-08-31 DK DK09782400.7T patent/DK2341937T3/da active
- 2009-08-31 MX MX2011003335A patent/MX2011003335A/es active IP Right Grant
- 2009-08-31 RU RU2011117293/10A patent/RU2531548C2/ru not_active IP Right Cessation
- 2009-08-31 KR KR1020117009215A patent/KR20110061630A/ko not_active Application Discontinuation
- 2009-08-31 WO PCT/EP2009/061210 patent/WO2010034590A1/en active Application Filing
- 2009-08-31 ES ES09782400.7T patent/ES2528419T3/es active Active
- 2009-08-31 JP JP2011528278A patent/JP2012504110A/ja active Pending
- 2009-08-31 CN CN200980143326.7A patent/CN102215867B/zh not_active Expired - Fee Related
- 2009-08-31 AU AU2009296078A patent/AU2009296078B2/en not_active Ceased
- 2009-08-31 PT PT97824007T patent/PT2341937E/pt unknown
- 2009-08-31 SG SG2013070859A patent/SG194362A1/en unknown
- 2009-08-31 CA CA2738598A patent/CA2738598C/en active Active
- 2009-08-31 BR BRPI0919489A patent/BRPI0919489A2/pt not_active IP Right Cessation
-
2011
- 2011-03-24 IL IL211904A patent/IL211904A/en not_active IP Right Cessation
- 2011-03-29 US US13/074,357 patent/US20110229465A1/en not_active Abandoned
- 2011-04-29 CR CR20110226A patent/CR20110226A/es not_active Application Discontinuation
- 2011-08-29 HK HK11109118.5A patent/HK1154797A1/xx not_active IP Right Cessation
-
2015
- 2015-05-13 JP JP2015097888A patent/JP6154847B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US20110229465A1 (en) | 2011-09-22 |
CR20110226A (es) | 2011-12-05 |
WO2010034590A1 (en) | 2010-04-01 |
PT2341937E (pt) | 2015-02-18 |
MX2011003335A (es) | 2011-04-27 |
RU2531548C2 (ru) | 2014-10-20 |
RU2011117293A (ru) | 2012-11-10 |
IL211904A (en) | 2016-03-31 |
HK1154797A1 (en) | 2012-05-04 |
SG194362A1 (en) | 2013-11-29 |
KR20110061630A (ko) | 2011-06-09 |
JP2012504110A (ja) | 2012-02-16 |
CN102215867A (zh) | 2011-10-12 |
CA2738598A1 (en) | 2010-04-01 |
ES2528419T3 (es) | 2015-02-09 |
AU2009296078A1 (en) | 2010-04-01 |
IL211904A0 (en) | 2011-06-30 |
CN102215867B (zh) | 2017-04-19 |
JP6154847B2 (ja) | 2017-06-28 |
BRPI0919489A2 (pt) | 2015-12-01 |
AU2009296078B2 (en) | 2015-08-20 |
JP2015172060A (ja) | 2015-10-01 |
CA2738598C (en) | 2017-11-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5597553B2 (ja) | 疾患治療剤 | |
US11866509B2 (en) | Humanized antibodies against CEACAM1 | |
EP2262838B1 (en) | Agent for treating disease | |
EP2260057B1 (en) | Anti-CD4 antibody dosage regimen for treating autoimmune disease | |
JP2019108341A (ja) | 腫瘍を標的としたil−2バリアント免疫サイトカインとヒトpd−l1に対する抗体との併用療法 | |
DK2341937T3 (da) | Sammensætning til behandling af en sygdom | |
CN107614522A (zh) | 多特异性免疫调节性抗原结合构建体 | |
KR102198998B1 (ko) | 신규한 항-cd40 항체 및 이의 용도 | |
MXPA01008098A (es) | Inmunoglobulina humanizada reactiva con moleculas b7 y metodo de tratamiento con el mismo. | |
EP2341937B1 (en) | Composition for treating disease | |
TW202417487A (zh) | 治療在t細胞受體內帶有trbv9節段的t淋巴細胞所介導的疾病或病症之方法 | |
US20200239562A1 (en) | Anti-il-33 therapy for atopic dermatitis | |
JP2024517985A (ja) | 抗-CD300cモノクローナル抗体及びその癌の予防または治療用バイオマーカー | |
WO2024040206A9 (en) | Pd-1 agonist antibodies and methods of treating autoimmune diseases with a pd-1 agonist antibody | |
TW202302146A (zh) | 使用抗baffr抗體治療全身性紅斑狼瘡 |